Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can intermittent fasting help paralyzed veterans lose weight?

NCT ID NCT05921487

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study looks at whether time-restricted eating (a form of intermittent fasting) is a practical way for veterans with spinal cord injury and obesity to lose weight. Fifteen veterans with paraplegia will try eating all their daily calories within a set window of time for 6 weeks. The goal is to see if they can stick with the plan and gather information for a larger future study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Sep 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Veteran * A member of the Spinal Cord Injury/Disorder (SCI/D) registry through the Syracuse VA, including both hub and spoke sites * A qualifying diagnosis of SCI within the SCI/D registry * Neurologic level of injury from T1 to S5, based on most recent Status Update or American Spinal Injury Association Impairment Scale (ASIA) examination, or a diagnosis of a hereditary form of paraplegia (such as familial spastic paraplegia or hereditary spastic paraplegia) * ASIA Impairment Scale grade A-D * Chronic SCI (\> 1 year from date of SCI or diagnosis of SCI) * BMI \> 22 - the BMI used to diagnose obesity in individuals with SCI * Mean eating window of at least 10 hours per day Exclusion Criteria: * Females who are pregnant (tested via urinary human chorionic gonadotropin (hCG)), planning to become pregnant in the next 6 months, or breast-feeding * A member of the SCI/D registry through the Syracuse VA, with a qualifying diagnosis of MS or ALS * Diagnosis of heart failure * Diagnosis of diabetes mellitus, type 1 * Diagnosis of diabetes mellitus, type 2, and on insulin or other antidiabetic agent with high incidence of hypoglycemia o Of note, antidiabetic agents with low incidence of hypoglycemia are: metformin, Glucagon-like peptide-1 (GLP-1) receptor agonists, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Dipeptidyl peptidase 4 (DPP-4) inhibitors, alpha glucosidase inhibitors, thiazolidinediones (as discussed with VA pharmacist) * Diagnosis of End Stage Renal Disease * Diagnosis of dementia * Diagnosis of orthostatic hypotension and prescribed midodrine or fludrocortisone * History of syncopal episode in the month prior to the study * History of significant weight loss (\> 10% body weight) in the month prior to the study * History of eating disorders (e.g., anorexia or bulimia) within the last five years, or clearance from a mental health provider * History of active suicidal ideation in the last six months, or clearance from a mental health provider * Currently prescribed weight loss medication (e.g., liraglutide) * Currently prescribed corticosteroids * Current acute medical issues including cancer, sepsis, advanced liver failure, porphyria, or uncontrolled hyperthyroidism

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Syracuse VA Medical Center, Syracuse, NY

    Syracuse, New York, 13210-2716, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.